Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Alzheimer's Medication Trials

St Louis, Missouri

Alzheimer's medication trials in St Louis, MO

11 Alzheimer's medication studies are recruiting participants at sites in St Louis as of November 17, 2026, according to ClinicalTrials.gov. Alzheimer's Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5916
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

St Louis at a glance

  • 11 studies are recruiting at a site in St Louis.
  • By phase: Phase 1 (1), Phase 2 (3), Phase 2/3 (3), Phase 3 (2), Phase 4 (2).
  • By sponsor: industry (6), university, hospital or other (5).
  • Most recent update to one of these records: November 5, 2026.

Studies recruiting in St Louis

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study site
    Tekton Research, LLC
    Registry record
    NCT06159673 · updated
  2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Tekton Research, LLC - Saint Louis Psychiatry - PPDS
    Registry record
    NCT06585787 · updated
  3. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    • Phase 4
    • Ages 50 and older
    • All sexes
    Sponsor
    Alpha Cognition, Inc
    Study sites
    Psympatica, LLC · Tekton Research Saint Louis Psychiatry
    Registry record
    NCT07633470 · updated
  4. A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

    • Phase 2
    • Ages 40 to 55
    • All sexes
    Sponsor
    Alnylam Pharmaceuticals
    Registry record
    NCT07636811 · updated
  5. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eidos Therapeutics, a BridgeBio company
    Study site
    Washington University in St. Louis
    Registry record
    NCT06563895 · updated
  6. Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

    • Phase 4
    • Ages 18 to 80
    • All sexes
    Sponsor
    Eidos Therapeutics, a BridgeBio company
    Study site
    Washington University in St. Louis
    Registry record
    NCT07695701 · updated
  7. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Washington University in St. Louis
    Registry record
    NCT05552157 · updated
  8. A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Washington University in St. Louis
    Registry record
    NCT06647498 · updated
  9. Sleep Trial to Prevent Alzheimer's Disease

    • Phase 2
    • Ages 65 and older
    • All sexes
    Sponsor
    University of Minnesota
    Study site
    Washington University School of Medicine
    Registry record
    NCT04629547 · updated
  10. DORA and LP in Alzheimer's Disease Biomarkers

    • Phase 2
    • Ages 65 and older
    • All sexes
    Sponsor
    University of Minnesota
    Study site
    Washington University in St. Louis, School of Medicine
    Registry record
    NCT06274528 · updated
  11. A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    • Phase 1
    • Ages 21 to 80
    • All sexes
    Sponsor
    University College, London
    Study site
    Washington University in St. Louis
    Registry record
    NCT06372821 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in St Louis, MO on ClinicalTrials.gov.

Ask about studies near St Louis

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

Alzheimer's Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5916

or send a short form

How should we reach you?

Call